key: cord-0794186-u9wt3qni authors: Recalcati, Sebastiano; Gianotti, Raffaele; Fantini, Fabrizio title: COVID-19: The experience from Italy date: 2020-12-17 journal: Clin Dermatol DOI: 10.1016/j.clindermatol.2020.12.008 sha: 1bdc73ae33269c9ee2726a31e5355b4f037bb6e1 doc_id: 794186 cord_uid: u9wt3qni A wide range of cutaneous signs are atributed to COVID-19 infection. This retrospective study assessed the presence and impact of dermatologic manifestations related to COVID-19 spread in Lombardy, the geographic district with the most important outbreak in Italy. A cohort of 345 patients with laboratory confirmed COVID-19 was collected from February 1 to May 31, 2020. Cutaneous signs and dermatologic diagnosis were recorded on admission and during the course of the disease. Of the 345 patients included in the study, 52 (15%) had new-onset dermatologic conditions related to COVID-19. We observed 7 major cutaneous clinical patterns, merged under 3 main groups: exanthems, vascular lesions. and other cutaneous manifestations. Each subset was detailed with prevalence, age, duration, prognosis and histology. Cutaneous findings can lead to suspect COVID-19 infection and identify potentially contagious cases with indolent course. In December 2019, the first cases of pneumonia with unknown cause were reported in Wuhan, China. 1 The new pathogen, a novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was isolated from samples from the lower respiratory tract of infected patients, 2 and the resulting disease was termed Coronavirus Disease 2019 . Since then, SARS-CoV-2 has rapidly spread, reaching the level of a pandemic disease. infection is characterized mainly by interstitial pneumonia which may progress to the acute respiratory distress syndrome. SARS-CoV-2 may also damage the heart, liver, kidneys, and other organ systems, including the blood and the immune system. Many affected patients have died from respiratory failure, shock, heart failure, and arrhythmias, as well as renal or multiple organ failures. 2 Due to the extraordinary outbreak and a physician shortage, several medical specialties, including dermatologists, were involved in this global fight against SARS-CoV-2. Recent reports from several countries have indicated that this novel coronavirus may be associated with cutaneous manifestations. These may be useful in identifying otherwise asymptomatic COVID-19 carriers, in order to slow down the viral transmission; however, the identification and characteristics of these dermatologic symptoms remain controversial. We report our retrospective cohort study which has assessed and characterized the cutaneous involvement during COVID-19. The data are taken from Lombardy, Italy, one of the region with the earliest outbreak. Our study investigated the epidemiologic, clinical, and histopathologic features of COVID-19 cutaneous manifestations observed between February 1 and May 31, 2020. The data were uniformly collected by experienced dermatologists at the Lecco Hospital, Lombardy, Italy. Some of our observation have been previously reported. [3] [4] [5] [6] [7] [8] [9] Data from both the inpatient (n=37) and outpatient services (n=15) were included. Patients were included only if there was laboratory confirmation of SARS-CoV-2 infection, regardelss of clinical signs and symptoms, according to the definitions created by the European Centre for Disease Control, were included. 10 A COVID-19 diagnosis was considered as laboratory-confirmed, if either nasopharyngeal swab for SARS-CoV-2 RNA detection or serology for anti-SARS-CoV-2 IgG/IgM by chemiluminescent immunoassay (CLIA) or ELISA yielded positive results. In the chilblain-like lesions setting, serologic studies using IgM/IgG rapid test were also conducted. Cutaneous signs and dermatologic diagnosis were recorded on admission. Epidemiologic, clinical, therapeutic, and outcome data were collected from patient medical records. Blood investigations were performed in most cases, while skin biopsies representative of every subsets were performed, whenever possible in some patiets. A complete dermatologic history was recorded, in order to discriminate between newly-occurred COVID-19 related pathologies and persistence/reactivation of pre-existing dermatologic conditions. We observed 345 patients with confirmed COVID-19. We recorded the histories for fifty-two patients (15%), aged 7 to 94 years (average 54.6 years), having new-onset dermatologic conditions and not pre-existing. There was no gender prevalence. Data are detailed in Table 1 . In thirty-eight percent of the cases, skin involvement was apparent at the onset of the infection, simultaneously with the flu-like presentation typical of the disease (we considered onset through the third day). The remaining 62% of the dermatologic cases were observed between 4 and 90 days after the onset of typicalCOVID-19 findings. The consensus following direct observation and image review led to the description of 7 major clinical patterns. Histopathologic examination showed a superficial and/or deep perivascular dermatitis with cuffs of lymphocytes surrounding blood vessels, dermal ducts, and eccrine glands. There were extravasated erythrocytes from damaged vessels in the upper portion of the dermis. Tissue from a few patients revealed a superficial band-like perivascular dermatitis with many necrotic keratinocytes ( Figure 5 B-C-D-E-F). In our experience, this setting was associated with a more severe course of COVID-19: these patients were often hospitalized and many placed on the intensive care units. Urticarial lesions were usually associated with a good prognosis, and these patients did not require hospitalization. Treatment included antihistamines, topical corticosteroids, and rarely systemic corticosteroids. Most lesions resolved in 3-4 weeks without treatment, while some patients experienced a prolonged course till 2 months. CLL were associated with a good prognosis. A.-Alopecia (11.5%) We observed 5 cases of severe telogen effluvium in patients previously hospitalized for COVID-19 ( Figure 4 A-C). Three cases deserved intensive care requirements. Latency of effluvium was consistent with hair follicle damage occurring 3 months before, during the SARS-CoV-2 infection. Patients complained of acute diffuse hair loss accompanied by trichodynia. In addition, a case of lichen planopilaris resulting in cicatricial alopecia was observed (Figure 4 B-E) . In this case a biopsy documented an ulcerated epidermis with a dense lymphocytic infiltration around hair follicles, and a few thrombosed vessels at the hair bulge. The dermis was diffusely fibrotic ( Figure 6 E-F). A few patients showed reactivation of other skin diseases such herpes simplex, herpes zoster and pityriasis rosea. Cutaneous manifestations following therapies or hospitalization were also reported, such as cutaneous adverse drug reactions and pressure sores due to pronation (Figure 4 C-F). Personal protective equipment and hand hygiene practices carried sometimes aggravation of preexisting skin conditions (acne, rosacea, seborrheic dermatitis, contact dermatitis) (Figure 4 D) . The group of "indirect cutaneous manifestations" has not contributed to prevalence calculation of cutaneous manifestations related to COVID-19. SARS-CoV-2 infection has been demonstrated to affect the skin, however data about prevalence of cutaneous involvement are lacking. Two previous articles reported a prevalence of 20.4% and 7.8%, respectively. 3, 4 In the present study we observed a prevalence of 15%. The study included both patients that were hospitalized and outpatients. We believe that many other patients with a COVID-19 related cutaneous rash did not seek medical advice, due to the absence of systemic symptoms, and therefore escaped dermatologic diagnosis. Moreover, skin lesions may have been neglected as their duration can be very short and symptoms mild. Therefore, cutaneous lesions are likely to have been underestimated. Similarly, the number of COVID-19 positive patients in the general population is likely underestimated, due to the low number of virologic tests performed. Thus, as far as prevalence is concerned, both numerator and denominator are underestimated. We believe that our prevalence estimate could be reliable because we included in our study both inpatients and outpatients. This cohort of patients could well reflect the prevalence of SARS-CoV-2-related skin involvement in the general population. Gender prevalence was uniform and middle-aged adults was the most involved group, even if disease can affect age transversely. An uncommon aspect of SARS-CoV-2 compared to other viruses, is its ability to determine a wide spectrum of cutaneous manifestations. We are used to link each exanthem to a particular virus or bacteria, but in this new pandemic usual schemes have to be reviewed. We described 7 major cutaneous clinical patterns associated with COVID-19, under 3 main groups. Exanthems were the most commonly reported skin manifestations. They are characteristic of an early viremic phase, similarly to rashes occurring in the course of other common viral infections. Purpura, observed in a few cases, could represent a secondary phenomenon during the natural evolution of the exanthem, perhaps enhanced by the altered coagulation state linked to SARS-CoV-2. In the group of vascular lesions, likely due to a delayed vasculophatic mechanism, a distinction was made between vasculitic lesions and CLL subset, because the latter was related to a welldefined setting of young patients, with reproducible lesions and always good prognosis. Cutaneous manifestations (excluding the telogen effluvium subset) began on average 6.9 days after the onset of COVID-19 symptoms. In 38% of the cases skin involvement was present from the beginning. The duration of dermatological manifestations was short (average 11.3 days). In the vascular lesions setting skin signs raised later and lasted longer (average 22.7 days). The sites of involvement in the exanthem group were mainly the trunk, while in the vascular lesions group were the extremities. Mucosal lesions were not recorded. Histopathology of COVID-19-related skin lesions shows different patterns, comparable to those already described in known dermatoses. These patterns have been linked to an immune dysregulation, either cell-mediated such as in erythema multiforme and lichen planus, or mediated by circulating immune complexes, such as in urticaria. Both viral and bacterial infections are common triggers of these patterns. with SARS-CoV-2 infection. Unfortunately, most cases in the majority of reported series to date lack confirmation of SARS-CoV-2 infection by PCR or serologic testing. 5, [11] [12] [13] [14] [15] [16] [17] [18] The prototype patient is asymptomatic or with minimal findings in a young adult. CLL should be considered a different phenotype than acro-ischemic lesions presenting in critical patients. 19 In a previous contribution, we hypothesized that the lesions might result from a delayed immunologic reaction against viral particles. 5 An increased type I interferon reaction has also been implicated. 20 Serologic non-reactivity could be due to the limitation of available commercial serologic tests. Alternatively, a vigorous innate immune response against the virus, able to control the infection without effectively generating antibodies through the adaptive response, may be implicated. If we consider in the CLL subset even the non-confirmed cases, data suggest that CLL develops in subjects with mild infection and low viral shedding who are unable to generate neutralizing antibodies. As a result, affected patients might not be protected from COVID-19 re-infection. Vascular lesions are probably due to an unbalanced coagulation state and might represent a COVID-19-specific complication. SARS-CoV-2 may induce a prothrombotic state, leading to the formation of microthrombi in the dermal vessels due to inflammation, platelet activation, and endothelial dysfunction. 8, 21 For these reasons, thromboprophylaxis is recommended for all hospitalized COVID-19 patients. 22 It is unknown if the cutaneous vascular lesions might signal vessel damage to other organs. With this assumption that CLL could be a marker of systemic vessel damage, such patients might benefit from antiplatelet or anti-inflammatory intervention. Cutaneous involvement during COVID-19 infection has been well documented. Prevalence in affected patients is likely around 15%. The power of this study is that all our cases had a laboratory confirmed diagnosis of COVID-19. The spectrum of skin manifestations is heterogeneous and can be grouped in three main settings: an exanthem usually simultaneous with the onset of the extracutaneous COVID-19 findings; a second subset consisting of vascular lesions arising later and lasting longer, and a miscellaneous group of various cutaneous manifestations, not directly linked to the viral action on the skin, is also observed. These results may help physicians to promptly identify COVID-19 related skin signs and to enhance our understanding of the pathogenetic mechanisms of the underlying the disease. The recognition of cutaneous manifestations in asymptomatic patients could be helpful for epidemiologic control, especially in areas where diagnostic tests are scarce. Lastly, these findings may prove useful for providing better patient management and prognosis. SARS-CoV-2 has completely changed our era and has modified our way of thinking about an infective disease. We are reminded of the time of HIV discovery a generation ago and raises new questions waiting to be answered: how many other new clinical manifestations do we expect? How many other diseases can it promote or reactivate? How long will the virus persist in affected patients? Studies on COVID-19 pathogenesis must continue, and we believe that unexpected findings could emerge in the future. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia Comorbidities and multi-organ injuries in the treatment of COVID-19 Cutaneous manifestations in COVID-19: a first perspective Cutaneous manifestations related to coronavirus disease 2019 (COVID-19): A prospective study from China and Italy Acral cutaneous lesions in the Time of COVID-19 Colchicin Treatment of Covid-19 Presenting With Cutaneous Rash and Myopericarditis Chilblain-like lesions during the COVID-19 pandemic: early or late sign? Histopathological Study of a Broad Spectrum of Skin Dermatoses in Patients Affected or Highly Suspected of Infection by COVID-19 in the Northern Part of Italy: Analysis of the Many Faces of the Viral-Induced Skin Diseases in Previous and New Reported Cases Cutaneous Clinico-Pathological Findings in three COVID-19-Positive Patients Observed in the Metropolitan Area of European Centre for Disease Prevention and Control. Case definition and European surveillance for COVID-19, as of 2 American Academy of Dermatology Ad Hoc Task Force on COVID-19. Pernio-like skin lesions associated with COVID-19: A case series of 318 patients from 8 countries Chilblain-like lesions on feet and hands during the COVID-19 Pandemic Chilblain-like lesions during COVID-19 epidemic: a preliminary study on 63 patients COVID-19) infection-induced chilblains: A case report with histopathologic findings Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases Characterization of acute acral skin lesions in nonhospitalized patients: A case series of 132 patients during the COVID-19 outbreak Novel outbreak of acral lesions in times of COVID-19: A description of 74 cases from a tertiary university hospital in Spain Are chilblain-like acral skin lesions really indicative of COVID-19? A prospective study and literature review Acral findings during the COVID-19 outbreak: Chilblain-like lesions should be preferred to acro-ischemic lesions Vascular skin symptoms in COVID-19: a French observational study Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA Abbreviations: r= reactive, n= non-reactive, np= not performed.